Top Things to Know: 2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease
Published: April 30, 2025
- This document describes performance measures for chronic coronary disease that are appropriate for public reporting or pay-for-performance programs.
- The performance measures are from the “2023 American College of Cardiology/American Heart Association Guideline for the Management of Patients With Chronic Coronary Disease” and are selected from the strongest recommendations (Class 1 or 3).
- Quality measures are also provided that are not yet ready for public reporting or pay for performance but might be useful to clinicians and health care organizations for quality improvement.
- Improved patient outcomes and reduced use of health care are significant reasons for the inclusion of an assessment of patient smoking status and counseling for cessation that includes behavioral or pharmacologic intervention.
- Several performance measures address appropriate antiplatelet therapy, medication selection for antihypertensive therapy, high-intensity statin use, and appropriate medical therapy for patients with chronic coronary disease with reduced ejection fraction.
- A performance measure focusing on inappropriate invasive and noninvasive testing is included that addresses the overuse of testing in patients with otherwise stable chronic coronary disease.
- A performance measure is included that reflects the expanding indications for cardiac rehabilitation, emphasizing the increasing importance of cardiac rehabilitation referral.
- A quality measure examining low-density lipoprotein cholesterol targets is included to optimize control of low-density lipoprotein levels in chronic coronary disease by attaining either a 50% reduction in low-density lipoprotein or low-density lipoprotein cholesterol levels of <70 mg/dL.
- For all measures, if the clinician determines the care is inappropriate for the patient, that patient is excluded from the measure.
- For all measures, patients who decline treatment or care are excluded.
Citation
Williams MS, Levine GL, Kalra D, Agarwala A, Baptiste D, Cigarroa JE, Diekemper RL, Foster MV, Gulati M, Henry TD, Itchhaporia D, Lawton JS, Newby LK, Rogers KC, Soni K, Tamis-Holland JE. 2025 AHA/ACC clinical performance and quality measures for patients with chronic coronary disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. Circ Cardiovasc Qual Outcomes. 2025;18:e000140. doi: 10.1161/HCQ.0000000000000140